Matthew Rabinowitz, who serves as Executive Chairman of Natera, Inc. (NASDAQ:NTRA), completed a series of transactions between March 12 and March 16, 2026 that included the sale of company common stock and the exercise of stock options.
Under a prearranged Rule 10b5-1 trading arrangement, Rabinowitz sold a total of 203,520 shares of Natera common stock. The share disposals were executed at prices spanning from $186.7494 to $198.0204 per share, and the aggregate proceeds from those sales amounted to roughly $38.3 million.
Concurrently, Rabinowitz exercised stock options that allowed him to acquire 200,000 shares at an exercise price of $9.59 per share. The cash outlay associated with those option exercises totaled $1,918,000.
After accounting for the sales and the option exercises, Rabinowitz directly holds 2,310,772 shares of Natera common stock. He also has an indirect interest in 5,000 additional shares through his spouse.
At the time of these transactions, Natera shares were trading at $197.68. That price point reflects a 32% gain over the preceding 12 months, while the stock remained down about 14% year-to-date.
Independent valuation analysis cited by InvestingPro indicates the stock appears overvalued when measured against its Fair Value estimate. InvestingPro also offers an extensive Pro Research Report covering NTRA as part of its coverage of more than 1,400 U.S. equities for investors seeking additional data.
On the operational front, Natera reported progress across several testing initiatives. The company’s Signatera circulating tumor DNA assay has produced encouraging results in studies involving anal squamous cell carcinoma and locally advanced rectal cancer. In those analyses, patients who tested negative for Signatera at baseline or who cleared ctDNA during treatment demonstrated strong one-year survival rates.
In addition, Natera introduced Zenith genomics, a whole genome sequencing test designed to diagnose rare genetic conditions, developed in collaboration with MyOme. The offering leverages advanced sequencing technology to deliver broad diagnostic coverage for rare disease workups.
From the sell-side, Morgan Stanley revised its price target on Natera to $250 from $265 while maintaining an Overweight rating, following adjustments to its financial model. Canaccord Genuity reiterated its Buy rating, pointing to fourth-quarter results that exceeded the company’s preannouncement and citing rising test volumes across Natera’s business units, particularly for Signatera.
Collectively, the insider transactions and the company’s clinical and product milestones underscore active capital and operational developments at Natera. The mix of insider selling, option exercising, analyst model updates and clinical progress will be of interest to market participants monitoring diagnostics and genomics exposures in the healthcare sector.